Skip to content
Head to head

Phibro Animal Health vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: PAHC · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

PAHC -25.2%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%).
PAHCTAK
Snapshot
Sector----
Last price33.2921.77
Change today-2.32%+1.68%
1-year return-17.4%+57.5%
Market cap$1.35B$69.76B
52-week range28.04 – 59.6413.92 – 22.07
Valuation
P/E (TTM)13.32311.00
P/E percentile, own 5-yr range20th100th
P/B3.241.50
Dividend yield1.44%1.44%
Profitability & growth
EPS (TTM)2.43-0.30
Net profit (TTM)$98.66M$-970.94M
Revenue (TTM)$1.54B$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+6.3%+6.7%
Gross margin33.8%65.8%
Operating margin12.5%14.3%
Net margin6.7%0.9%
Free cash flow (TTM)$21.67M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership54.7%51.3%
Insider activity (12mo)17 buy / 33 sell19 buy / 31 sell
Short interest (% of float)2.5%0.1%
Analyst consensus50% buy / 50% sell (2)100% buy (1)
Analyst price target$45 (+35%)$50 (+132%)
StockVane view
StockVane Quant RatingD (21)C (90)
Company
Employees2,60547,029
Founded19461781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.